A phase II study with CD20-positive non-Hodgkin's lymphoma treated with shorter duration of infusion of GA101(RO5072759)
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2016
At a glance
- Drugs Obinutuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms GATS trial
- Sponsors Chugai Pharmaceutical; Nippon Shinyaku
- 06 Dec 2016 Results assessing safety and pharmacokinetics presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 07 Nov 2016 Last checked against Japan Pharmaceutical Information Center - Clinical Trials Information record.
- 27 Oct 2016 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History